Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM)

Cardiovascular
0
Pipeline Programs
2
Companies
1
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

2 companies ranked by most advanced pipeline stage

Ionis Pharmaceuticals
1 program
Scintigraphy scanN/A
AstraZeneca
AstraZenecaCAMBRIDGE, United Kingdom
1 program
Scintigraphy scanN/A1 trial
Active Trials
NCT06073587Active Not Recruiting150Est. Mar 2026

Trial Timeline

Clinical trial activity over time

2023
2024
2025
2026
AstraZenecaScintigraphy scan

Clinical Trials (1)

Total enrollment: 150 patients across 1 trials

NCT06073587AstraZenecaScintigraphy scan

The CARDIO-TTRansform Scintigraphy Sub-study

Start: Apr 2023Est. completion: Mar 2026150 patients
N/AActive Not Recruiting

Related Jobs in Cardiovascular

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

2 companies competing in this space